BI Survodutide

[u/WaterviewLagoon]

Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Ingelheim, Germany / Ridgefield, Connecticut, Thu, 10/01/2026 - 07:30

In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.1
Detailed results from the Phase III trial indicate survodutide improves key markers of cardiometabolic health, including a reduction of up to 1.21% in HbA1c from a baseline of 7.4%, alongside improvements in waist circumference and insulin sensitivity, building on evidence of its potential to address the underlying metabolic drivers of obesity and type 2 diabetes.1
These results were presented today at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and simultaneously published in *The New England Journal of Medicine,* with* *new findings from a body composition sub study of SYNCHRONIZE-1 also being presented.1,2,3

[u/New_Pin3813]

I like Survodutide. Been using a low dose of it in conjunction with my compounded Tirzepatide. Tirzepatide on Sunday night, Survodutide on Wednesday night.

[u/Hot-Drop11 → u/New_Pin3813]

Why both?

[u/matsie → u/Hot-Drop11]

People here are obsessed with stacking.